CureVac disappoints in COVID vaccine trial
Nature Podcast
00:00
Vaxzines - Kurva vs Kuva?
Noah Smith: A vaxcine company now that's taken a notably different approach to two very successful vaxzines, and it's come up short. What's this going to mean for vaxing development going forward? He says if you know that works and this one has problems, i think a lot of the field is just going to go with the modifications.Smith: We've still got to watch for the second generation from kuva. There are still other vacines that are in development, and there's going to be more results coming from then.
Transcript
Play full episode
